scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.INTIMP.2017.11.032 |
P698 | PubMed publication ID | 29202299 |
P2093 | author name string | Olivier Fardel | |
Valérie Lecureur | |||
Abdullah Mayati | |||
Marie Febvre-James | |||
Yu Augagneur | |||
P2860 | cites work | Infection of a human hepatoma cell line by hepatitis B virus | Q34388628 |
P921 | main subject | ruxolitinib | Q7383611 |
P304 | page(s) | 354-365 | |
P577 | publication date | 2017-12-01 | |
P1433 | published in | International Immunopharmacology | Q15751306 |
P1476 | title | Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages | |
P478 | volume | 54 |
Q96618090 | COVID-19: review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking |
Q63246372 | Characterization and Transcript Expression Analyses of Atlantic Cod |
Q91587430 | Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib |
Q92954842 | Pre-hematopoietic cell transplant Ruxolitinib in patients with primary and secondary myelofibrosis |
Q95276341 | SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc |
Q107547771 | SARS-CoV-2 disrupts proximal elements in the JAK-STAT pathway |
Q97416174 | The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19 |
Search more.